Vaxxinity, Inc. is a U.S.-based biotechnology company looking to develop vaccines for several hard-to-treat diseases such as Alzheimer’s and Parkinson’s.
The company is pioneering a new class of medicines through its proprietary technology platform, which has enabled the innovation of novel synthetic peptide immunotherapy candidates to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia.
In this week’s podcast, the company’s CEO, Mei Mei Hu, tells us about its work, and the aim of democratizing healthcare across the globe.
01:00-02:21: About Vaxxinity
02:21-03:39: How does Vaxxinity’s approach differ from other companies?
03:39-04:38: How important is being able to roll out products globally?
04:38-06:28: What is your new class of vaccines?
06:28-08:58: How are you tackling diseases that are difficult to treat?
08:58-10:10: How does your Vaxxine Platform work?
10:10-10:58: Do synthetic peptides make this more scalable?
10:58-12:02: How are you addressing safety?
12:02-13:03: What has the reaction been like to your company?
13:03-14:14: What diseases are you tackling?
14:14-15:40: What is your pipeline for taking on these conditions?
15:40-16:16: Do you vaccines need booster shots?
16:16-18:17: Are you looking to cure diseases?
18:17-20:02: Could your approach be applied to other diseases?
20:02-20:29: Are you looking to partnerships?
20:29-21:10: What are the next steps?
21:10-21:24: When do you expect to see data?
21:24-21:42: When do you hope to have products being delivered to patients?
21:42-24:37: How does your COVID vaccine differ from others?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter